Dabur Pharma announces results for Fiscal 2006-07

Dabur Pharma announces results for Fiscal 2006-07
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney master your money IThe Winning Leap SME Special
Moneycontrol

Home » News » Business

May 17, 2007, 08.06 PM | Source: Moneycontrol.com

Dabur Pharma announces results for Fiscal 2006-07

Dabur Pharma announces results for Fiscal 2006-07

Like this story, share it with millions of investors on M3

Dabur Pharma announces results for Fiscal 2006-07

Dabur Pharma announces results for Fiscal 2006-07

Post Your Comments

Share Cancel

Annual Sales at Rs. 322 crores, growth of 19% over 05-06. Profit after Tax up 36% to Rs. 25.2 crores

Q4 sales up 12.4  % to Rs 59.60 crores; profit before tax for the same period up by 396% to Rs 349.64 lakhs.

 

 

The Board of Dabur Pharma Limited (DPL) (NSE: DABURPHARM, BSE: 532545) met here today to consider the audited financial results of the company for the quarter & fiscal ended 31st March 2007.

 

Financial Results

 

The company’s sales grew by 19% during the year to end at Rs. 322 crores, up from Rs. 270 crores during the previous year. Profit (before tax) also increased by 34% from Rs. 22.32 crores to Rs. 29.91 crores during the same period.

 

During the quarter, the company posted a 12.4% increase in its turnover from Rs 53.01 crores to Rs 59.60 crores. Profit (before tax) increased from Rs 70.50 lacs to Rs 349.64 lakhs during the quarter.

 

Commenting on the growth, Dr. Anand Burman, Chairman Dabur Pharma Limited, said “FY 2006-07 was a milestone year for the company, a year of significant growth, research and innovation that led to the launch of an array of new products, including Nanoxel – the first indigenously developed nanotechnology based chemotherapy agent in the country”.

 

Speaking on the occasion, Mr. Ajay K. Vij, CEO, Dabur Pharma Limited said “We’re very excited about our ventures in some key markets like US & EU and have intensified our development efforts to bring molecules to these markets much faster than before. Also, through the acquisition of the Thai business and the divestment of our non-oncology portfolio to Alembic, the Company is poised for highly focused growth”.

  

Sourced From : Imprimis Life PR Pvt Ltd

Buy, Hold, Sell ? Hear it first on M3
Dabur Pharma announces results for Fiscal 2006-07
Platinum Member
1114 Followers

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login